-
Mashup Score: 4
– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy- – If approved,…
Source: newsroom.astellas.usCategories: General Medicine News, PayerTweet
-
Mashup Score: 3Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy - 1 month(s) ago
Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), today announced the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique,…
Source: newsroom.astellas.usCategories: General Medicine News, PayerTweet
-
Mashup Score: 18
VYLOY approved in combination with chemotherapy for patients with human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer…
Source: newsroom.astellas.usCategories: General Medicine News, PayerTweet
-
Mashup Score: 3Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting - 1 month(s) ago
– If approved, XTANDI would become the first and only NHT treatment available for metastatic and high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patient…
Source: newsroom.astellas.usCategories: General Medicine News, PayerTweet
-
Mashup Score: 2From Recurrence to Perseverance: Jim's Prostate Cancer Story - 2 month(s) ago
As a civilian partner working for the Army for many years following his time in Vietnam, Jim didn’t suspect anything was amiss when he went for his annual health exam in 2006. However, during…
Source: newsroom.astellas.usCategories: General Medicine News, PayerTweet
-
Mashup Score: 5Astellas Names Michael Petroutsas as Head of US Commercial - 2 month(s) ago
Today, Astellas Pharma Inc. Chief Commercial Officer Claus Zieler has named Michael Petroutsas as Head, United States Commercial, leading the Astellas Pharma US Inc. organization. Petroutsas will…
Source: newsroom.astellas.usCategories: General Medicine News, PayerTweet
-
Mashup Score: 11
Astellas is returning to the Super Bowl to help educate game viewers about VEOZAH and vasomotor symptoms (VMS), the most commonly reported menopause symptoms1 The “Fewer Hot Flashes, More Not Flashes”
Source: newsroom.astellas.usCategories: General Medicine News, PayerTweet
-
Mashup Score: 9
Astellas is returning to the Super Bowl to help educate game viewers about VEOZAH and vasomotor symptoms (VMS), the most commonly reported menopause symptoms1 The “Fewer Hot Flashes, More Not Flashes”
Source: newsroom.astellas.usCategories: General Medicine News, PayerTweet
-
Mashup Score: 0
– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy – – If approved,…
Source: newsroom.astellas.usCategories: General Medicine News, PayerTweet
-
Mashup Score: 2
– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival – – If approved, PADCEV with KEYTRUDA would be the…
Source: newsroom.astellas.usCategories: General Medicine News, PayerTweet
Our application has been accepted by China’s National Medical Products Administration for a combination therapy for advanced #UrothelialCancer, investigated with @Pfizer_news and Merck. Read more: https://t.co/eO2OI9HwUT https://t.co/lGxM8GHXyl